Publisher
Springer Science and Business Media LLC
Reference56 articles.
1. Morkel, M., Riemer, P., Blaker, H. & Sers, C. Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. Oncotarget 6, 20785–20800 (2015).
2. Dempke, W. C. & Heinemann, V. Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma. Anticancer research 30, 4673–4677 (2010).
3. Temraz, S., Mukherji, D. & Shamseddine, A. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers. International journal of molecular sciences 16, 22976–22988,
https://doi.org/10.3390/ijms160922976
(2015).
4. Fritsche-Guenther, R. et al. Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis. Oncotarget 7, 7960–7969,
https://doi.org/10.18632/oncotarget.6959
(2016).
5. Fritsche-Guenther, R. et al. Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. Molecular systems biology 7, 489, doi:msb201127 (2011).
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献